The Information License Agreement (ILA) requires two types of reporting related to use of CME Term SOFR: standard market data use reporting and “notional reporting”. One or both types of reporting may be required, depending on your use of CME Term SOFR. Standard market data reporting captures the quantity and type of use by license and is auditable under the ILA. Notional reporting is also a requirement under the ILA but is used by CME Group to meet UK Benchmark Regulation (UK BMR) reporting requirements. It captures the outstanding notional value of the financial products, issued by UK supervised entities, that reference CME Term SOFR under the Category 1 and Category 2 Use licenses. Here we will discuss these requirements in more detail and provide sample reporting formats.

**Standard Reporting**

Standard market data reporting requirements vary by license type and are submitted to CME using the Data Service Portal.

- **Display Devices** – Reporting obligations for accessing CME Term SOFR in Display Devices will begin in January 2023.
  - Where CME Term SOFR is accessed for viewing on a screen provided by a licensed data distributor then;
    - The distributor alone will report directly to CME, the total quantity of display devices with access to the data by your firm.
    - The total quantity of devices, in aggregate, is reported on a location basis each month.
    - For each location, the report captures, Firm Name, Firm Address, and total quantity of devices with access to the CME Term SOFR data.
    - No personal or user level information is required to be reported.
  - Where CME Term SOFR is accessed for viewing on a screen, and the access to Display Devices is managed by the license holder (Licensee),
    - Licensees are required to report directly to CME, the total quantity of Display Devices with access to the data.
    - The total quantity of devices, in aggregate, is reported on a location basis each month.
    - For each location, Firm Name and Firm Address are required, as well as the total number of devices at each of those locations. This is firm level information only, not personal or user level information.
    - CME provides a reporting template in Excel format. It can be downloaded from the CME Data Services Portal which can be accessed [here](#). A sample reporting template can also be found [here](#).
    - Completed templates should be submitted using the same portal. Your firm will be provided access to this portal to enable you to submit these reports each month. Below is a screenshot of where you will be asked to submit your report.
Note that any display device that is provided by a licensed distributor will be reported by that distributor only. The same level of information and detail is required from the distributor. No personal or user level information is required.

For additional information please refer to the Unit of Count: Device guide.

- **Non-Display**
  - Licensee of CME Term SOFR for Non-Display Benchmark Use have no reporting obligation for such use.

- **Category 3**
  - Licensee of CME Term SOFR for Category 3 Use have no reporting obligation for such use.
**Notional Reporting**

- **Category 1 and Category 2 Licenses**
  - CME Benchmark Administration, Ltd. is subject to UK BMR that requires CBA to report to the regulator the outstanding notional of financial products, issued by UK Supervised Entities that reference CME Term SOFR. This helps the regulator determine the use of and systemic importance of the benchmark.
  - CME, therefore, requires licensees to report the total outstanding notional of their financial products that reference CME Term SOFR, issued by UK supervised entities.
  - The following products are in scope of reporting:
    - **Category 1**
      - Bonds and Floating Rate Notes
      - Retail Mortgages
      - Retail Loans
      - Money Market Instruments (e.g., Commercial Paper, Repo, Certificates of Deposit)
      - Outstanding notional of non-retail loans and Structured Notes is not required to be reported.

---

Please populate **CME Term SOFR Usage Notional Value ($)** Category 1 (in $millions) used as reference in Cash Market Financial Products by type of product. This should be reflective of outstanding notional as of 31st Jan 2023.

- The scope is cash market financial products issued by a UK Supervised Entity.

**Note:** Outstanding notional of non-retail loans and Structured Notes is not required to be reported based on current requirements

<table>
<thead>
<tr>
<th>Type of Product</th>
<th>Notional Value ($millions)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sum of Bond/Floating Rate Notes (FRNs)</td>
<td>$</td>
</tr>
<tr>
<td>Sum of Retail Mortgages</td>
<td>$</td>
</tr>
<tr>
<td>Sum of Retail Loans</td>
<td>$</td>
</tr>
<tr>
<td>Sum of Money Market Instruments (e.g., Commercial Paper, Repo)</td>
<td>$</td>
</tr>
</tbody>
</table>
Category 2

- All OTC Derivative Hedge Products

Licensees can report at an individual product level, at the overall Category level or as a single aggregated notional across Category 1 and Category 2 products combined.

- The request to report, a point in time assessment, will come in January of each year and will be due in February.

- Where a licensee does not have a UK supervised entity in its group that has issued financial products that reference CME Term SOFR, a figure of $0 is required to be submitted.

- Where a licensee is unable to differentiate between notional attributable to its UK supervised entities and other entities within its group, the licensee should report the outstanding notional at a group level.

- This requirement will commence in 2023.

Audit

In order to help customers be compliant with the ILA, from time to time, and no more than once in a 12-month period, CME may conduct an audit of data usage in respect of the licensees’ usage of Term SOFR.

The audit may take place remotely, or in-person, and will be co-ordinated with the licensee at a suitable time with 30-days’ notice.

All information observed during an audit will be treated as confidential information and used only to verify compliance with the agreement.

Typically, we compare your license and reporting to your data management infrastructure – any entitlement systems you have, records of access and identifying the role of your applications processing the data. If we find any discrepancies, we will walk you through those and identify methods of remediation, which could include a financial settlement in respect of under-reporting of fee-labile access.

In respect of CME Term SOFR licensing, we will not ask for personal user information.
Exchange traded derivatives and cleared over-the-counter ("OTC") derivatives are not suitable for all investors and involve the risk of loss. Exchange traded and OTC derivatives are leveraged instruments and because only a percentage of a contract's value is required to trade, it is possible to lose more than the amount of money initially deposited. This communication does not (within the meaning of any applicable legislation) constitute a prospectus or a public offering of securities; nor is it a recommendation to buy, sell or retain any specific investment or service. The content in this communication has been compiled by CME Group for general purposes only and is not intended to provide, and should not be construed as advice. Although every attempt has been made to ensure the accuracy of the information within this communication as of the date of publication, CME Group assumes no responsibility for any errors or omissions and will not update it. Additionally, all examples and information in this communication are used for explanation purposes only and should not be considered investment advice or the results of actual market experience. Any information denoting past or historical performance is not indicative of future performance and no reliance shall be placed on such information. All matters pertaining to rules and specifications herein are made subject to and superseded by official CME, CBOT, NYMEX and COMEX rulebooks. Current rules should be consulted in all cases including matters relevant to contract specifications. CME Group does not represent that any material or information contained in this website is appropriate for use or permitted in any jurisdiction or country where such use or distribution would be contrary to any applicable law or regulation.

In Australia, each of Chicago Mercantile Exchange Inc. (ABN 103 432 391), The Board of Trade of the City of Chicago Inc (ABN 110 594 459), the New York Mercantile Exchange Inc (ABN 113 929 436) and Commodity Exchange, Inc. (ABN 622 016 193) is a registered foreign company in Australia and holds an Australian market licence. In Hong Kong, CME Group is authorised by the Hong Kong Securities and Futures Commission (the "SFC") to provide Automated Trading Services ("ATS") via its GLOBEX system, and its CME Clearing System under Part III of the Securities and Futures Ordinance (the "SFO"). In Japan, CME Inc. has a Foreign Clearing Organisation (FCO) license under the Financial Instruments and Exchange Act of Japan. In Singapore, CME Inc., CBOT, NYMEX and COMEX are regulated as a recognized market operator and CME Inc. is regulated as a recognized clearing house under the Securities and Futures Act (Chapter 289) ("SFA"). Save as aforesaid, none of the CME Group entities are licensed to carry on regulated activities under the SFA or to provide financial advisory services under the Financial Advisers Act (Chapter 110) in Singapore. None of CME Group entities are registered or licensed to provide, nor does it purport to provide, financial services of any kind in some jurisdictions, including, but not limited to, India, Korea, Malaysia, New Zealand, People's Republic of China, Philippines, Taiwan, Thailand, and Vietnam and in any jurisdiction where CME Group is not authorized to do business or where such distribution would be contrary to the local laws and regulations. The contents of this communication have not been reviewed by any regulatory authority in Hong Kong. You are advised to exercise caution in relation to the information contained herein. If you are in any doubt about any of the contents of this communication, you should obtain independent professional advice. CME is not licensed to carry on business in dealing or advising on futures contracts under the Securities and Futures Ordinance in Hong Kong. In Japan, this communication is for distribution solely to certain qualified sophisticated investors as defined in the Commodities Futures Act of Japan (Law No. 239 of 1950, as amended) and the related rules, as appropriate; other than that, the information contained in this communication is not directed at any person in Japan. In the Republic of Korea, this communication is for distribution solely to "professional investors" (as defined in Article 9(5) of the Financial Investment Services and Capital Markets Act and related rules) in response to a request from such professional investors or through a licensed investment broker. In Singapore, this communication and its contents have not been reviewed or approved by any regulatory authority in Singapore. The information within this communication has been compiled by CME Group for general purposes only and is not intended to provide, and should not be construed as, advice. It does not take into account your objectives, financial situation or needs, you should obtain appropriate professional advice before acting on or relying on the information set out in this communication. The information within this communication should not be considered as an offer, invitation or solicitation to buy or sell any futures, options contracts or any other financial products or services. CME Group assumes no responsibility for any errors or omissions. Additionally, all examples in this communication are hypothetical situations, used for explanation purposes only, and should not be considered investment advice or the results of actual market experience. This communication is for distribution in Singapore solely to persons holding a capital markets services licence for trading in futures contracts or exempt from such requirements.

In these jurisdictions, this communication has not been reviewed or approved by any regulatory authority and access shall be at the liability of the user. Any trades undertaken in the aforesaid jurisdictions will be at the sole risk of the relevant investor and should always be made in compliance with the local laws and regulations applicable in such jurisdictions.

CME Group, the Globe Logo, CME, Globex, E-Mini, CME Direct, CME DataMine and Chicago Mercantile Exchange are trademarks of Chicago Mercantile Exchange Inc. CBOT and the Chicago Board of Trade are trademarks of the Board of Trade of the City of Chicago, Inc. NYMEX and ClearPort are trademarks of New York Mercantile Exchange, Inc. COMEX is a trademark of Commodity Exchange, Inc. Copyright © 2022 CME Group Inc. All rights reserved. Mailing Address: 20 South Wacker Drive, Chicago, Illinois 60606.

CME Group Benchmark Administration Limited (CBA), Chicago Mercantile Exchange Inc. (including each of their respective subsidiaries and affiliates), their respective officers, directors, employees, agents, consultants and licensors shall not be liable to any person for any losses, damages, costs or expenses (including, but not limited to, loss of profits, loss of use, and direct or indirect, incidental, consequential or punitive damages), arising from any errors or inaccuracies made in connection with the calculation or distribution of the CME Term SOFR Reference Rates. The foregoing limitation of liability shall apply whether a claim arises in contract, tort, negligence, strict liability, contribution or otherwise and whether the claim is brought directly or as a third party claim. Furthermore, there is no guarantee the continuity of the composition of the CME Term SOFR Reference Rates, nor the continuity of their calculation, nor the continuity of their dissemination, nor the continuity of their calculation.